15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $761M | $100M | 98.3% | 5.9% | $142M | — | $120M |
| 2024 | $675M | $141M | 98.4% | 20.3% | $196M | — | $128M |
| 2023 | $482M | $106M | 98.7% | 22.2% | $127M | — | $136M |
| 2022 | $402M | $101M | 98.7% | 28.0% | $120M | — | $66M |
| 2021 | $366M | $113M | 98.6% | 34.0% | $167M | — | $78M |
| 2020 | $354M | $106M | 98.4% | 36.2% | $151M | — | $76M |
| 2019 | $306M | $94M | 98.2% | 36.4% | $135M | — | $31M |
| 2018 | $251M | $75M | 97.9% | 35.6% | $115M | — | $42M |
| 2017 | $159M | $129M | 97.8% | 33.2% | $61M | $0 | $31M |
| 2016 | $81M | $8M | 97.5% | 12.5% | $18M | $15M | $52M |
| 2015 | — | -$6M | — | — | — | $27M | $40M |
| 2014 | — | -$31M | — | — | — | $34M | $24M |
| 2013 | — | -$46M | — | — | -$37M | $35M | $55M |
| 2012 | — | -$38M | — | — | -$36M | $45M | $93M |
| 2012 | — | -$220M | — | — | -$192M | — | $43M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $165M | -$32M | 98.3% | -30.1% | -$17M | — | $109M |
| Dec '25 | $202M | $24M | 98.7% | 2.2% | $38M | — | $120M |
| Sep '25 | $208M | $20M | 97.8% | 4.9% | $54M | — | $125M |
| Jun '25 | $194M | $35M | 98.2% | 13.7% | $44M | — | $103M |
| Mar '25 | $157M | $21M | 98.5% | 2.2% | $5M | — | $90M |
| Dec '24 | $182M | $31M | 98.4% | 13.9% | $60M | — | $128M |
| Sep '24 | $183M | $47M | 98.4% | 25.5% | $72M | — | $137M |
| Jun '24 | $164M | $35M | 98.5% | 21.7% | $41M | — | $129M |
| Mar '24 | $147M | $28M | 98.3% | 20.1% | $24M | — | $150M |
| Dec '23 | $135M | $31M | 98.6% | 23.4% | $6M | — | $136M |
| Sep '23 | $124M | $31M | 98.7% | 25.2% | $53M | — | $112M |
| Jun '23 | $118M | $28M | 98.7% | 25.1% | $42M | — | $172M |
| Mar '23 | $106M | $16M | 98.7% | 14.1% | $26M | — | $300M |
| Dec '22 | $103M | $17M | 98.6% | 21.8% | $33M | — | $66M |
| Sep '22 | $102M | $35M | 98.7% | 31.4% | $33M | — | — |
| Jun '22 | $103M | $27M | 98.7% | 30.4% | $18M | — | $35M |
| Mar '22 | $94M | $23M | 98.7% | 28.6% | $35M | — | $62M |
| Dec '21 | $99M | $32M | 98.6% | 37.1% | $49M | — | $78M |
| Sep '21 | $96M | $30M | 98.7% | 37.7% | $49M | — | $95M |
| Jun '21 | $92M | $27M | 98.5% | 34.9% | $44M | — | $95M |
How the market has priced CORT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Corcept Therapeutics Inc's revenue has grown 16.6% per year, and net income declined 1.2% per year. These are computed facts, not advice.
As of FY2025, Corcept Therapeutics Inc reported — of total debt against $120M of cash.
In FY2025, gross margin was 98.3%, operating margin 5.9%, and net margin 13.1%.
As of Jun '26, Corcept Therapeutics Inc traded at a price-to-earnings ratio of about 91.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.